<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593018</url>
  </required_header>
  <id_info>
    <org_study_id>ORACLE</org_study_id>
    <nct_id>NCT03593018</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL</brief_title>
  <official_title>Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of Oral azacitidine versus single-agent Investigator's&#xD;
      Choice Therapy in patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared to B-cell Non-Hodgin Lymphoma (NHL), Angioimmunoblastic T-cell Lymphoma (AITL) is&#xD;
      more resistant to conventional chemotherapy and is generally associated with an inferior&#xD;
      outcome. In case of relapsed of refractory disease, survival durations are in the range of&#xD;
      only a few months.&#xD;
&#xD;
      Several agents have been evaluated in this setting in recent years: romidepsin, bendamustine&#xD;
      or belinostat. The response rate with these agents rarely exceeds 30% and responses are&#xD;
      usually of limited duration.&#xD;
&#xD;
      Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with&#xD;
      various myelodysplastic syndrome (MDS) subtypes. In this case, azacitidine significantly&#xD;
      increase the survival time compared to standard of care option. This response to azacitidine&#xD;
      could be correlated to the existence of recurrent mutations and those mutations have also&#xD;
      been described in AITL.&#xD;
&#xD;
      The present protocol will use Azacitidine according to the same schedule than in MDS that is&#xD;
      continuous treatment until progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 months after first randomisation (when 18 events will occur)</time_frame>
    <description>PFS using local assessment of progressive disease according to Lugano Response Criteria (2014)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>35 months after first randomisation (when 61 events will occur)</time_frame>
    <description>PFS using local assessment of progressive disease according to Lugano Response Criteria (2014)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by the Independent Review Committee (IRC)</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>PFS by the Independent Review Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>Percentage of Complete Response (CR)+ Partial Response (PR) among all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>Percentage of CR among all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TtR)</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>Time to response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS 2 using local assessment of progressive disease</measure>
    <time_frame>40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation</time_frame>
    <description>PFS 2 using local assessment of progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire (QLQ-C30)</measure>
    <time_frame>2 years after last randomisation</time_frame>
    <description>questionnaire at baseline and at least one follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAE)</measure>
    <time_frame>2 years after last randomisation</time_frame>
    <description>Treatment discontinuation, adverse events, deaths</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Relapsed Angioimmunoblastic T-Cell Lymphoma</condition>
  <condition>Refractory Angioimmunoblastic T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Oral Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator's choice therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral azacitidine</intervention_name>
    <description>Azacitidine tablets</description>
    <arm_group_label>Oral Azacitidine</arm_group_label>
    <other_name>CC-486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Romidepsin injection</description>
    <arm_group_label>Investigator's choice therapy</arm_group_label>
    <other_name>Istodax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine injection</description>
    <arm_group_label>Investigator's choice therapy</arm_group_label>
    <other_name>Levact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine injection</description>
    <arm_group_label>Investigator's choice therapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must satisfy all following criteria to be enrolled in the study::&#xD;
&#xD;
          1. Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).&#xD;
&#xD;
          2. Patient must understand and voluntarily sign an ICF prior to any study-specific&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          3. Patient is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          4. Patient had local diagnosed peripheral T cell lymphoma (PTCL) with T-follicular helper&#xD;
             (TFH) phenotype according to the criteria of the latest World Health Organization&#xD;
             (WHO) classification based on a surgical lymph node biopsy including any one of&#xD;
&#xD;
               -  Angioimmunoblastic T cell lymphoma (AITL)&#xD;
&#xD;
               -  Follicular T cell lymphoma&#xD;
&#xD;
               -  Nodal peripheral T-cell lymphoma with TFH phenotype There should be a documented&#xD;
                  expression of minimum two TFH markers among this panel of markers : CD10, CXCL13,&#xD;
                  PD1, ICOS and BCL6 by the tumoral cells by immunohistochemistry. Biopsy at&#xD;
                  relapse or progression is not mandatory, but highly encouraged on a surgical or&#xD;
                  needle core biopsy, and diagnostic tissue should be available for central&#xD;
                  pathology review and for ancillary molecular studies.&#xD;
&#xD;
             Local pathology report should be reviewed by the sponsor's medical monitor prior to&#xD;
             enrollment.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3&#xD;
&#xD;
          6. Relapsed (after partial or complete response) or refractory AITL after at least one&#xD;
             line of systemic therapy (there is no mandatory resting period after the previous&#xD;
             treatment as long as the biochemistry and hematology labs meet the inclusion criteria&#xD;
             as below.)&#xD;
&#xD;
          7. Meet the following lab criteria:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1,5 x 109/L (≥ 1 x 109/L if bone marrow (BM)&#xD;
                  involvement by lymphoma)&#xD;
&#xD;
               -  Platelet ≥ 75 x 109/L (≥ 50 x 109/L if BM involvement by lymphoma)&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL.&#xD;
&#xD;
          8. Anticipated life expectancy at least 3 months&#xD;
&#xD;
          9. At least one measurable lesion on CT that is greater than 1.5 cm in the longest&#xD;
             diameter for nodal lesions and greater than 1.0 cm in the longest diameter for&#xD;
             extranodal lesions. The lesion must be measurable in two perpendicular dimensions.&#xD;
             Patients with only cutaneous disease will be excluded.&#xD;
&#xD;
         10. Female patient of childbearing potential (FCBP) may participate, providing she meets&#xD;
             the following conditions:&#xD;
&#xD;
             Have two negative pregnancy tests as verified by the investigator prior to starting&#xD;
             study treatment: serum pregnancy test at Screening and negative serum or urine&#xD;
             pregnancy test (investigator's discretion) within 72 hours prior to starting treatment&#xD;
             with study treatment (Cycle 1 Day 1). She must agree to ongoing pregnancy testing&#xD;
             during the study (before beginning each subsequent cycle of treatment), and 28 days&#xD;
             after the last study drug administration. This applies even if the patient practices&#xD;
             complete abstinence from heterosexual contact.&#xD;
&#xD;
             Agrees to practice true abstinence (which must be reviewed monthly and source&#xD;
             documented) or agrees to the use of highly effective methods of contraception from 28&#xD;
             days prior to starting study treatment, and must agree to continue using such&#xD;
             precautions during study treatment (including dose interruptions) and for up to 90&#xD;
             days after the last study drug administration. True abstinence is acceptable when this&#xD;
             is in line with the preferred and usual lifestyle of the patient. Periodic abstinence&#xD;
             (eg, calendar, ovulation, symptom-thermal, post ovulation methods) and withdrawal are&#xD;
             not acceptable methods of contraception. Cessation of contraception after this point&#xD;
             should be discussed with a responsible physician.&#xD;
&#xD;
             Agrees to abstain from breastfeeding during study participation and for at least 90&#xD;
             days after the last study drug administration.&#xD;
&#xD;
             A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at&#xD;
             some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has&#xD;
             not been naturally postmenopausal (amenorrhea following cancer therapy does not rule&#xD;
             out childbearing potential) for at least 24 consecutive months (i.e., has had menses&#xD;
             at any time during the preceding 24 consecutive months).&#xD;
&#xD;
         11. Male patient must either practice true abstinence from heterosexual contact (which&#xD;
             must be reviewed on a monthly basis and source documented) or agrees to avoid&#xD;
             fathering a child, to use highly effective methods of contraception, male condom plus&#xD;
             spermicide during sexual contact with a pregnant female or a female of childbearing&#xD;
             potential (even if he has undergone a successful vasectomy), from starting dose of&#xD;
             drug (cycle 1 Day 1), including dose interruptions through 90 days after receipt of&#xD;
             the last study drug administration. Furthermore, male patient must agree to not give&#xD;
             semen or sperm during study drug therapy and for a period of 1 year after end of study&#xD;
             drug therapy.&#xD;
&#xD;
         12. For EU countries, patient covered by a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Presence of any of the following will exclude a patient from enrollment:&#xD;
&#xD;
          1. Clinical evidence of central nervous system involvement by lymphoma. Patients with&#xD;
             suspicion of central nervous system (CNS) involvement must undergo neurologic&#xD;
             evaluation and CT/MRI of head and lumbar puncture to exclude CNS disease.&#xD;
&#xD;
          2. Any significant medical conditions, laboratory abnormality or psychiatric illness&#xD;
             likely to interfere with participation in this clinical study (according to the&#xD;
             investigator's decision)&#xD;
&#xD;
          3. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing&#xD;
             signs/symptoms related to the infection without improvement despite appropriate&#xD;
             antibiotics, antiviral therapy, and/or other treatment)&#xD;
&#xD;
          4. Known Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV) infection, or&#xD;
             evidence of positive HTLV1 serology or of active Hepatitis B (HB) Virus (HBV)&#xD;
             infection defined as:&#xD;
&#xD;
               -  HB s Ag positive&#xD;
&#xD;
               -  HB s Ag negative, anti-HB s antibody positive and/or anti-HB c antibody positive&#xD;
                  with detectable viral DNA&#xD;
&#xD;
          5. Impaired renal function (MDRD formula or Cockcroft-Gault Creatinine Clearance &lt; 30&#xD;
             ml/min) or impaired liver function tests (Serum total bilirubin level &gt; 2.0 mg/dl [34&#xD;
             µmol/L] (except in case of Gilbert's Syndrome, or documented liver or pancreatic&#xD;
             involvement by lymphoma), Serum transaminases (AST or ALT) &gt; 3 upper normal limits)&#xD;
             unless they are related to the lymphoma.&#xD;
&#xD;
          6. Active malignancy other than the one treated in this research. Prior history of&#xD;
             malignancies, other than low risk MDS or chronic myelomonocytic leukemia (CMML) (with&#xD;
             less than 5% blasts in bone marrow), unless the patient has been free of the disease&#xD;
             for ≥ 3 years. However, patients with the following history/concurrent conditions are&#xD;
             allowed:&#xD;
&#xD;
               1. Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               2. Carcinoma in situ of the cervix&#xD;
&#xD;
               3. Carcinoma in situ of the breast&#xD;
&#xD;
               4. Incidental histologic finding of prostate cancer (T1a or T1b) using the&#xD;
                  tumor-nodes-metastasis (TNM)] clinical staging system&#xD;
&#xD;
               5. Early-stage gastric cancer suitable for endoscopic mucosal resection or&#xD;
                  endoscopic submucosal dissection&#xD;
&#xD;
          7. Treatment with any investigational drug within 5 half-lives before planned first cycle&#xD;
             of study treatment and during the study. Ongoing medically significant adverse events&#xD;
             from previous treatment, regardless of the time period.&#xD;
&#xD;
          8. Prior exposure to azacitidine and/ or any other demethylating agent (eg, decitabine)&#xD;
&#xD;
          9. Prior exposure to planned study treatment investigator's choice therapy (eg, prior&#xD;
             exposure to gemcitabine is an exclusion if gemcitabine is the investigator's choice&#xD;
             therapy prior to randomization)&#xD;
&#xD;
         10. Concurrent use of corticosteroids unless the patient is on a stable or decreasing dose&#xD;
             for ≥ 1 week prior to informed consent form signature&#xD;
&#xD;
         11. Knowing or suspected hypersensitivity to active substance or to any of the excipients.&#xD;
&#xD;
         12. Pregnant, planning to become pregnant, or lactating woman&#xD;
&#xD;
         13. Candidate for hematopoietic stem cell transplantation&#xD;
&#xD;
         14. History of active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any&#xD;
             other gastrointestinal disorder or defect that would interfere with the absorption,&#xD;
             distribution, metabolism or excretion of the oral azacitidine and/or predispose the&#xD;
             patient to an increased risk of gastrointestinal toxicity per investigator's decision.&#xD;
             Any condition causing inability to swallow tablets.&#xD;
&#xD;
         15. Significant active cardiac disease within the previous 6 months, including:&#xD;
&#xD;
               -  New York Heart Association (NYHA) class IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina or angina requiring surgical or medical intervention; and/or&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
         16. Person deprived of his/her liberty by a judicial or administrative decision&#xD;
&#xD;
         17. Adult person under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jehan DUPUIS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Henri Mondor University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François LEMONNIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Henri Mondor University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kunihiro TSUKASAKI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saitama Medical University International Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital for Internal Medicine - University Hospital Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medical University</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. Z. Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Bruges</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires de Bruxelles - Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Catholique de Louvain Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand - Hôpital Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Lévèque - Centre François Magendie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.lysarc.org/</url>
    <description>Website of The Lymphoma Study Research Organisation (LYSARC)</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral azacitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

